Open Access<p>Allopurinol in Patients with Pulmonary Hypertension Associated with Chronic Lung Disease</p>
Author(s) -
Patrick Sk Liu-Shiu-Cheong,
Brian J. Lipworth,
Jonathan R. WeirMcCall,
J. Graeme Houston,
Allan D. Struthers
Publication year - 2020
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s260917
Subject(s) - medicine , allopurinol , copd , placebo , xanthine oxidase , cardiology , spirometry , pulmonary hypertension , gastroenterology , asthma , pathology , biochemistry , chemistry , alternative medicine , enzyme
Oxidative stress (OS) has been implicated in the development of pulmonary hypertension (PH) and ventricular hypertrophy. Xanthine oxidase is a well-recognised source of reactive oxygen species, which lead to OS. The aim of this proof of concept study was to assess whether allopurinol (xanthine oxidase inhibitor) would reduce right ventricular mass (RVM) in patients with PH-associated chronic lung disease (PH-CLD).